Pharmaceuticals News and Research

RSS

Omnicare Clinical Research attains Rave Accredited Plus in Medidata’s ASPire to Win program for CRO's

Medidata Solutions, a leading global provider of hosted clinical development solutions, today announced that global contract research organization (CRO) Omnicare Clinical Research has attained Rave Accredited Plus, the most advanced level in Medidata’s ASPire to Win® program for CROs and other service providers.

28 Oct 2009

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced it led a $17.4 million Series B financing round for Quinnova Pharmaceuticals, Inc., with participation from existing investors Thomas, McNerney & Partners and H.I.G. BioVentures.

28 Oct 2009

Gamma Pharmaceuticals inks brokerage agreement with J&A Lazier Racing

Gamma Pharmaceuticals Inc. announced it has signed a Product Brokerage Agreement with J&A Lazier Racing LLC of California. Mr. Lazier, an accomplished Indy Car Driver, will benefit from Gamma's Professional Grade vitamin supplements, nutritional and energy products to ensure peak athletic performance during the demanding Indy Car season.

28 Oct 2009

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

The California Institute of Quantitative Biosciences (QB3) is collaborating with a newly launched $7.5 million fund to provide startup capital for University of California bioscience entrepreneurs and a long-term endowment for QB3.

28 Oct 2009

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), announced today that the United States Patent and Trademark Office (USPTO) has allowed a patent application within the ‘Esau’ patent family (US Application Serial No. 10/909,125).

28 Oct 2009

Pure Protein develops soluble Class II human leukocyte antigens

Pure Protein, L.L.C., a biopharmaceutical company specializing in diagnostic and therapeutic reagents for use in immunology research and development, has announced that Chief Scientist William Hildebrand, Ph.D., and his team, have developed soluble Class II human leukocyte antigens (HLA). This represents a significant technology breakthrough that can dramatically impact multiple pharmaceutical and medical sectors and has enormous market potential. Autoimmune disease is a key area of interest for HLA research and product development.

28 Oct 2009

Accenture Innovation Center for Health launched to tackle challenges facing the global health industry

Accenture (NYSE: ACN) today launched the Accenture Innovation Center for Health in response to the growing global demand for insights into and strategies to confront the top health issues and challenges affecting citizens worldwide. The center serves as the focal point for Accenture’s thought capital and proven assets for tackling the most pressing challenges facing the global health industry.

28 Oct 2009

DSM Biomedical announces new non-biofouling coating technology for medical applications

DSM Biomedical, a global leader in biomedical materials, today announced the development of VitroStealth™, a breakthrough non-biofouling (NBF) coating technology. Specifically developed to combine state of the art non-biofouling properties with high durability and fast processing, VitroStealth™ coating is scratch resistant and reduces unwanted protein absorption and cellular adhesion on surfaces.

28 Oct 2009

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

Results from the largest prospective controlled ulcerative colitis (UC) trial conducted to date, called the QD dosing investigation for efficacy IN UC maintenance (QDIEM), found that once-daily dosing of Asacol(R) (mesalamine) delayed-release 400 mg tablets at 1.6-2.4 g/day was comparable to twice-daily dosing for the maintenance of remission in patients with UC.

28 Oct 2009

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

SciClone Pharmaceuticals, Inc. today announced a corporate restructuring that will reduce its U.S.-based workforce by approximately 17%, primarily in research and development. This restructuring follows the discontinuation of SciClone's RP101 phase 2 clinical trial announced on October 2, 2009.

28 Oct 2009

MolecularMD moves core operations to expanded facility

MolecularMD Corp announced today that it has moved their core operations to a expanded dedicated facility with capacity and functionality to support the expansion of its cancer molecular diagnostics business.

28 Oct 2009

Global sales volumes of Levulan Kerastick exceed one million units

DUSA Pharmaceuticals, Inc.®, a specialty pharmaceutical company focused on dermatology, announced today that global sales volumes of the Levulan® Kerastick®, an integral part of the Levulan® Photodynamic Therapy (PDT) technology platform, surpassed one million units.

28 Oct 2009

Veeva CRM to be implemented at Adamas Pharmaceuticals

Adamas Pharmaceuticals, an emerging pharmaceutical company focused on developing small-molecule therapeutics to treat neurological and infectious diseases, selected Veeva System’s VBioPharma™ KOL Edition – part of the Veeva CRM suite. Selection of Veeva’s SaaS solution marks an important step in Adamas’ early-stage product commercialization strategy.

28 Oct 2009

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2009. For the third quarter of 2009, Auxilium reported net revenues of $42.1 million compared to net revenues of $32.6 million in the third quarter of 2008.

28 Oct 2009

NSF awards $3 million grant for establishing a Partnership in Research and Education in Materials

Professor Morris is principal investigator on a new, five-year $3 million National Science Foundation (NSF) grant that establishes a Partnership in Research and Education in Materials (PREM) at CCNY in collaboration with the University of Chicago's Materials Research Science and Engineering Center. The "overarching goal of the partnership is to develop methodology for description of material dynamics" as an emerging branch of materials science.

28 Oct 2009

Urigen Pharmaceuticals announces a presentation on interstitial cystitis/painful bladder syndrome

Urigen Pharmaceuticals, Inc., focused on the development of treatments for urologic disorders and pain, announces a presentation at its offices on October 30, 2009 at 2PM PST. The slides presented will be posted to its website at www.urigen.com after the close of trading that day.

28 Oct 2009

Deloitte releases "Acquisitions versus Product Development: An Emerging Trend in Life Sciences" report

Recent pharmaceutical mergers and acquisitions indicate a trend of consolidation in the industry. Companies are looking for ways to bolster their research and development pipelines and reduce costs by rationalizing their combined sales and reducing other corporate overhead.

28 Oct 2009

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

InfoMedics, Inc., a company that engages patients and physicians to communicate better through the delivery of treatment feedback, has poster presentations at three industry conferences in October 2009. All of these studies provide a unique look at real-life patient feedback regarding experiences with medications for chronic conditions including ulcerative colitis (UC) and attention-deficit/hyperactivity disorder (ADHD) in adults and children.

28 Oct 2009

A.P. Pharma to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market

A.P. Pharma, a specialty pharmaceutical company, today announced that on October 26, 2009, the Company received notice that the Nasdaq Listing Qualifications Panel (Panel) has granted the Company’s request to transfer the listing of the Company’s common stock from The Nasdaq Global Market to The Nasdaq Capital Market, which will take effect with the opening of the market on Wednesday, October 28, 2009.

28 Oct 2009

New clinical uses for old hypertension drug leads to several patents

University of South Florida neuroscientist R. Douglas Shytle's discovery of successful new clinical uses for mecamylamine, a drug once used to treat hypertension, has led to several issued patents on mecamylamine and related compounds. Earlier this month, Shytle, associate professor and research scientist at the USF Center of Excellence for Aging and Brain Repair and the USF Silver Child Development Center, received the university's 2009 "Excellence in Innovation" award.

28 Oct 2009

Pharmaceuticals News and Research

Omnicare Clinical Research attains Rave Accredited Plus in Medidata’s ASPire to Win program for CRO's

Quinnova Pharmaceuticals raises $17.4 million through Series B financing

Gamma Pharmaceuticals inks brokerage agreement with J&A Lazier Racing

QB3 collaborates with Mission Bay Capital Fund to provide startup capital for UC scientists

United States Patent and Trademark Office allows a patent application within ‘Esau’ patent family

Pure Protein develops soluble Class II human leukocyte antigens

Accenture Innovation Center for Health launched to tackle challenges facing the global health industry

DSM Biomedical announces new non-biofouling coating technology for medical applications

Controlled trial in UC meets primary endpoint of non- inferiority for reducing ulcerative colitis

SciClone Pharmaceuticals reduces its U.S.-based workforce by 17% in research and development

MolecularMD moves core operations to expanded facility

Global sales volumes of Levulan Kerastick exceed one million units

Veeva CRM to be implemented at Adamas Pharmaceuticals

Auxilium Pharmaceuticals reports increased net revenues of $42.1 million in third quarter 2009

NSF awards $3 million grant for establishing a Partnership in Research and Education in Materials

Urigen Pharmaceuticals announces a presentation on interstitial cystitis/painful bladder syndrome

Deloitte releases "Acquisitions versus Product Development: An Emerging Trend in Life Sciences" report

Study of ‘real-life’ experiences of patients undergoing 5-ASA treatment for ulcerative colitis

A.P. Pharma to transfer listing from The Nasdaq Global Market to The Nasdaq Capital Market

New clinical uses for old hypertension drug leads to several patents

A guide to density measurement excellence eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring